^
    Back
    Association details:
    Biomarker:BAP1 mutation
    Cancer:Mesothelioma
    Drug:Tazverik (tazemetostat) (EZH2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

    Excerpt:
    ...Part 2: Molecular evidence of BAP1 loss of function mutation present on local pathology, e.g., lack of nuclear BAP1 staining by immunohistochemistry (IHC) or evidence of loss of function by gene sequencing 7....
    Trial ID:
    NCT02860286
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.

    Published date:
    05/13/2020
    Excerpt:
    The study enrolled 74 pts with R/R malignant mesothelioma, 70 pts (95%) were centrally confirmed to be BAP1-deficient....Based on disease control rate and stable disease, TAZ showed antitumor activity in pts with BAP1-deficient R/R malignant mesothelioma.
    DOI:
    10.1200/JCO.2020.38.15_suppl.9058
    Trial ID:
    NCT02860286